A Randomized, Double-blind, Open for Active Comparator, Parallel, Multi-center Phase II Study to Explore the Efficacy, Safety and Tolerability of BG2109 Compared With Cetrorelix During COH in Female Subjects Undergoing ART Procedures

BG2109-AC-201

To explore the optimal effective daily dose of BG2109 to suppress premature luteinizing hormone (LH) surge during COH in female subjects undergoing ART procedures.

2023-08-01

2024-06-01

2024-12-01

Not yet recruiting

Early phase I

240

Inclusion Criteria: * Married infertile women aged 20 to 39 years (both inclusive), who are diagnosed with tubal infertility, unexplained infertility, grade I-II endometriosis, or spouses diagnosed with male factor infertility, who meet the criteria for IVF and/or ICSI) using fresh or frozen semen from the male spouse or sperm donor * BMI 18-25 kg/m2 (both inclusive), body weight range 45-80kg (both inclusive) * Subjects must have regular menstrual cycles, specifically defined as ≥25 days, ≤35 days. * The serum sex hormone levels during the screening period must be performed in the early follicular phase, and the basal serum follicle-stimulating hormone (FSH) \<10 IU/L, LH, estradiol(E2), prolactin(PRL),testosterone(T) levels are within the laboratory normal range, or the investigator considers them as abnormal but not clinically significant * The subject is clinically assessed and agree to undergo fresh cycle embryo transfer in the first IVF-ET/ ICSI-Embryo Transfer(ET) cycle, with a maximum of two embryos transferred. * Within 1 year before randomization, the presence of bilateral ovaries is clearly visible on transvaginal ultrasonography with no significant abnormalities, and appendages are normal. Both ovaries must be available for oocyte retrieval * Subjects must sign the Informed Consent Form (ICF) and be willing and able to abide by the protocol-specified study procedures Exclusion Criteria: * Those who have undergone 2 or more COH of IVF/ICSI-ET before screening, but have not achieved clinical pregnancy. * Those with previous IVF or ART failure due to sperm/fertilization problems whose related medical condition has not been improved. * Either subjects or their spouses or both of them are known to carry abnormal chromosomal structures, or patients known to have single-gene genetic diseases or serious diseases with genetic susceptibility requiring Preimplantation Genetic Diagnosis(PGD) before embryo transfer. * Those with high risk of ovarian hyperstimulation syndrome(OHSS) * Those with low ovarian function at screening, with at least one of the following: poor ovarian response in the past; less than 6 antral follicles (AFC) with a diameter of \< 10 mm seen on bilateral ovary transvaginal ultrasonography at Day2-3 of menstrual cycle; anti-mullerian hormone(AMH) \< 1.1 ng/ml. * Subjects who used gonadotropins for ovarian stimulation or drugs that affect ovarian function within 30 days prior to screening. * Subjects with abnormal thinprep cytology test(TCT) results that are judged by the investigator as clinically significant and require treatment within 6 months before screening. * As judged by the investigator, subjects with clinically significant gynecological diseases at screening * Those previously or prior randomization suffering from the cancer of uterine, ovarian, breast or hypothalamus or pituitary gland. * Those with a positive serum β-hCG test result at the screening visit or the visit on Day 1 of ovarian stimulation. * During COH, LH ≥10 U/L, and the LH level was 2.5 times higher than the baseline value before D0 (inclusive).

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'Masked for BG2109 dose groups and open for the active controlled group.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 240, 'type': 'ESTIMATED'}}

2023-07-27